Clinical trial NCT06230822: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Official title: A Phase I Open Label, Dose Escalation Study to Characterize the Safety, Tolerability, and Efficacy of VUM02 Injection in Subjects With Idiopathic Pulmonary Fibrosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Idiopathic Pulmonary Fibrosis
Lead sponsor: Vcanbio Cell and Gene Engineering Corp., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-01-30
Enrollment: 9
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: VUM02 Injection (hUCT-MSCs)+Conventional treatment
Primary purpose: TREATMENT

Brief summary: This study is a single-arm, multiple-dose, dose-escalation, open-label multicenter clinical trial, aiming to evaluate the safety, tolerability, and preliminary efficacy of VUM02 Injection for treatment of idiopathic pulmonary fibrosis (IPF). VUM02 Injection (Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection, hUCT-MSC) is an allogeneic cell therapy product comprising culture-expanded Mesenchymal Stem Cells derived from the human umbilical cord tissue. The product is cryopreserved with the amount of 5 x 10\^7 cells per 10 mL per bag (5 x 10\^6 cells/mL). This study is a multiple-dose tolerability study following the "3+3" dose escalation principle and progressing from the low-dose group to the high-dose group sequentially. Three to six patients will be enrolled in each dose group and administered every 3 days for a total of 3 doses.

Detailed description: This trial includes three predefined dose groups: low dose (5E7 cells/person/time), medium dose (1E8 cells/person/time), and high dose (2E8 cells/person/time) groups, for a multiple-dose tolerability study. Each dose group undergoes an initial safety and tolerability assessment with a single dose. After receiving the initial dose, subjects undergo safety evaluations on Day 3 (including symptom assessment, physical examination, vital signs monitoring, 12-lead electrocardiogram, hematology, urinalysis, blood biochemistry, and coagulation function tests). The decision to proceed with subsequent administrations for subjects who have received the initial dose is made through discussion between the investigator and the sponsor (and/or CRO medical staff) based on safety profiles.

This study follows the "3+3" dose escalation principle, progressing from the low-dose group to the high-dose group sequentially. The sample size may be adjusted based on the actual circumstances of the trial, with each subject receiving only one corresponding dose. During the study, a Safety Monitoring Committee (SMC) will be established, consisting of the investigators and representatives from the sponsor. The SMC will review the safety data generated during the study and make decisions regarding dose escalation, modification of escalation doses, alteration of dosing regimens, or study discontinuation. Only after all subjects in the preceding dose group have completed the dose-limiting toxicity (DLT) observation, and the SMC confirms that the dose escalation criteria are met, the enrollment for the next dose group will begin.

Eligibility criteria: Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for this trial:

1. Gender unrestricted, aged between 40 and 75 years old (inclusive);
2. Diagnosed with IPF according to the 2022 Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
3. In the 3 months prior to administration, determined by the investigator to have stable disease, with diffusing capacity of the lung for carbon monoxide (DLCO) between 30% and 79% of the predicted value (adjusted for Hb), FVC/predicted ≥50%, and forced expiratory volume in one second (FEV1)/FVC ≥0.70;
4. Allowed to enroll are the patients who have been treated according to the current standard treatment plan for IPF and have maintained the treatment for at least 3 months;
5. Good compliance, able to understand and cooperate with pulmonary function test procedures, willing to participate voluntarily in the trial according to the protocol requirements, and understand and sign the informed consent form voluntarily.

Exclusion Criteria:

Patients meeting any of the following criteria are not eligible for this trial:

1. Allergic to any ingredient of the product;
2. Suffering from interstitial lung diseases (ILD) other than IPF, including but not limited to: any other type of interstitial pneumonia; lung diseases related to exposure to fibrogenic agents or other environmental toxins or drugs (such as amiodarone, bleomycin, or methotrexate); other types of occupational lung diseases; granulomatous lung diseases; systemic diseases including vasculitis, infectious diseases (i.e., tuberculosis), and connective tissue diseases, or a history of prior pulmonary resection;
3. During the screening period, having any of the following pulmonary diseases: asthma, pulmonary embolism, pneumothorax; lung cancer, obstructive bronchitis, or other active lung diseases; a known history of immune system diseases (such as thymic diseases, systemic lupus erythematosus); acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
4. Chest HRCT during the screening period shows emphysema area \> fibrosis area;
5. Previously received stem cell therapy or intolerant to cell therapy;
6. Received unstable standard of care for IPF within the 3 months prior to screening;
7. Used non-biological drugs with cell proliferation inhibition or immunosuppressive/immunomodulatory effects during the 3 months prior to screening, such as Mycophenolate Mofetil, cyclophosphamide, tacrolimus, and JAK inhibitors, as well as other Chinese herbal medicines with immunomodulatory effects;
8. Used biologics such as rituximab, TNF-α monoclonal antibodies, and IFN-γ monoclonal antibodies within the 6 months prior to screening;
9. Used anticoagulant drugs, sildenafil, bosentan, macitentan, imatinib, and other drugs for treating IPF within the 4 weeks prior to screening;
10. Participated in interventional clinical studies within the 3 months or within the half-life of 5 drugs (whichever is longer) before screening;
11. Hospitalized 2 or more times in the past year due to acute exacerbation of IPF;
12. Had a lung infection within the past month;
13. Had a history of invasive or non-invasive mechanical ventilation, or currently require oxygen therapy (oxygen therapy time \>15 h/d);
14. Smoked within the past 3 months or cannot quit smoking during the trial;
15. The expected survival period may be less than 1 year judged by investigator;
16. Laboratory tests meet any of the following criteria: white blood cell count less than 3.5×109/L or neutrophils less than 1.5×109/L for any reason; hemoglobin (HGB) ≤90 g/L; fibrinogen (FIB) ≤0.5×LLN; alanine aminotransferase (ALT) \>2×ULN, aspartate aminotransferase (AST) \>2×ULN, total bilirubin (TBIL) \>1.5×ULN, direct bilirubin (DBIL) \>1.5×ULN, blood creatinine (Cr) \>1.5×ULN;
17. Evidence suggests that the subject currently has digestive system, urinary system, cardiovascular system, hematological system, nervous system, psychiatric, or metabolic diseases that may affect safety, such as severe kidney disease requiring blood dialysis or peritoneal dialysis; advanced hepatitis or cirrhosis; severe heart failure (NYHA Grade III and IV); poorly controlled hypertension (≥180/100 mmHg); severe pulmonary heart disease or pulmonary arterial hypertension considered by the investigators to affect the evaluation of the trial results;
18. Have various malignant tumors or a history of malignant tumors;
19. 12-lead electrocardiogram shows severe arrhythmias (such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, and atrial flutter) or degree II and above atrioventricular block;
20. Positive results in serological tests (HBsAg, HCV antibodies, HIV antibodies, syphilis spirochete antibodies), among which carriers of hepatitis B virus, stable patients with hepatitis B (DNA titer ≤2000 IU/mL or copy number \<1000 copies/mL) after drug treatment, and cured patients with hepatitis C (negative HCV RNA) can be enrolled after being judged eligible by the investigator;
21. Pregnant or lactating women, or those with a positive result in the screening period for beta-human chorionic gonadotropin (β-HCG) testing; or male subjects of childbearing potential and female subjects of childbearing age who are unable and unwilling to take effective non-drug contraceptive measures during the study and 6 months after the end of the study;
22. Subjects deemed inappropriate for entry into this study by the investigator.

Primary outcomes:
measure: Incidence and severity of cell therapy-related adverse events (AEs) as assessed by CTCAE (V5.0)
timeFrame: 28 days
measure: Maximum tolerated dose (MTD)
timeFrame: 28 days
Secondary outcomes:
measure: Incidence and severity of treatment- emergent adverse events
timeFrame: 24 weeks
measure: DLCO changes from baseline
timeFrame: At baseline, 1, 4, 12 and 24 weeks
measure: FVC changes from baseline
timeFrame: At baseline, 1, 4, 12 and 24 weeks
measure: Exercise capacity changes from baseline
timeFrame: At baseline, 1, 4, 12 and 24 weeks
measure: St. George's Respiratory Questionnaire
timeFrame: At baseline, 1, 4, 12 and 24 weeks
measure: Symptoms of dyspnea
timeFrame: At baseline, 1, 4, 12 and 24 weeks
measure: Symptoms of cough
timeFrame: At baseline, 1, 4, 12 and 24 weeks
measure: Tumor biomarkers
timeFrame: At baseline, 12 and 24 weeks
measure: Chest imaging changes
timeFrame: At baseline, 12 and 24 weeks
measure: Acute exacerbations of IPF
timeFrame: 24 weeks
measure: T lymphocyte subpopulations
timeFrame: At baseline, 1, 4 and 12 weeks
measure: IgG and IgM levels
timeFrame: At baseline, 12 or 4 weeks
measure: Inflammatory cytokines
timeFrame: At baseline, 1, 4 and 12 weeks
measure: Serum complement levels
timeFrame: At baseline, 1, 4 and 12 weeks
measure: Blood proteomics analysis
timeFrame: At baseline, 1, 4, 12 and 24 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
city: Chengdu
country: China
facility: West China Hospital of Sichuan University
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Guangzhou Medical University
city: Kashi
country: China
facility: The First People's Hospital of Kashi Prefecture, Xinjiang
Study officials:
References: